Novel insights into muscarinic acetylcholine receptor function using gene targeting technology

Trends in Pharmacological Sciences

Volumn 24, Issue 8, 2003, Pages 414-420

  Wess, Jürgen ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N (3 CHLOROPHENYL)CARBAMOYLOXY] 2 BUTYNYLTRIMETHYLAMMONIUM CHLORIDE; DOPAMINE; MORPHINE; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; OXOTREMORINE; PILOCARPINE; RECEPTOR SUBTYPE; SCOPOLAMINE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; BRAIN BLOOD VESSEL; CORPUS STRIATUM; DOPAMINE RELEASE; DRUG EFFECT; ELECTROPHYSIOLOGY; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENE TECHNOLOGY; HYPOPHAGIA; LEAN BODY WEIGHT; MAZE TEST; MOUSE STRAIN; MUSCLE FUNCTION; NONHUMAN; NUCLEUS ACCUMBENS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SALIVATION; SEIZURE; SMOOTH MUSCLE; VASODILATATION;

EID: 0042661213     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00195-0     Document Type: Review

References (67)

1. Levine R.R., et al. Proceedings of the Eighth International Symposium on Subtypes of Muscarinic Receptors. Life Sci. 64:1999;355-593.
2. Levine R.R., et al. Proceedings of the Ninth International Symposium on Subtypes of Muscarinic Receptors. Life Sci. 68:2001;2449-2642.
3. Eglen R.M., et al. Muscarinic receptor ligands and their therapeutic potential. Curr. Opin. Chem. Biol. 3:1999;426-432.
4. Felder C.C., et al. Therapeutic opportunities for muscarinic receptors in the central nervous system. J. Med. Chem. 43:2000;4333-4353.
5. Caulfield M.P., Birdsall N.J.M. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 50:1998;279-290.
6. Wess J. Molecular biology of muscarinic acetylcholine receptors. Crit. Rev. Neurobiol. 10:1996;69-99.
7. Hamilton S.E., et al. Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13311-13316.
8. Gomeza J., et al. Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;1692-1697.
9. 4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10483-10488.
10. 3 subtype. Proc. Natl. Acad. Sci. U. S. A. 97:2000;9579-9584.
11. Yamada M., et al. Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature. 410:2001;207-212.
12. 1 muscarinic acetylcholine receptor. J. Neurosci. 21:2001;5239-5250.
13. Gerber D.J., et al. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;15312-15317.
14. 5 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14096-14101.
15. Fisahn A., et al. Muscarinic induction of hippocampal gamma oscillations requires coupling of the M1 receptor to two mixed cation channels. Neuron. 33:2002;615-624.
16. Takeuchi J., et al. Increased drinking in mutant mice with truncated M5 muscarinic receptor genes. Pharmacol. Biochem. Behav. 72:2002;117-123.
17. 4 muscarinic receptor knockout mice. Life Sci. 68:2001;2457-2466.
18. 4 receptor subtypes using receptor knockout mice. Life Sci. 68:2001;2473-2479.
19. Levey A.I., et al. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J. Neurosci. 11:1991;3218-3226.
20. Levey A.I. Immunological localization of M1-M5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci. 52:1993;441-448.
21. Wolfe B.B., Yasuda R.P. Development of selective antisera for muscarinic cholinergic receptor subtypes. Ann. N. Y. Acad. Sci. 757:1995;186-193.
22. Quirion R., et al. Muscarinic receptor subtypes in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol. Sci. 10:(Suppl.):1989;80-84.
23. Fisher A., et al. M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update. Ann. N. Y. Acad. Sci. 777:1996;189-196.
24. 1 muscarinic receptor mutant mice. Nat. Neurosci. 6:2003;51-58.
25. Hammer R., Giachetti A. Muscarinic receptor subtypes: M1 and M2 biochemical and functional characterization. Life Sci. 31:1982;2991-2998.
26. 1 muscarinic acetylcholine receptor. J. Pharmacol. Exp. Ther. 301:2002;129-137.
27. 2+ channels by using knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10899-10904.
28. 1 receptors. Neurosci. Lett. 278:2000;61-64.
29. 1 receptor is required for muscarinic activation of mitogen-activated protein (MAP) kinase in murine cerebral cortical neurons. J. Biol. Chem. 276:2001;15850-15853.
30. 1 Muscarinic acetylcholine receptors activate extracellular signal-regulated kinase in CA1 pyramidal neurons in mouse hippocampal slices. Mol. Cell. Neurosci. 18:2001;512-524.
31. Porter A.C., et al. M1 muscarinic receptor signaling in mouse hippocampus and cortex. Brain Res. 944:2002;82-89.
32. Bymaster F.P., et al. Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur. J. Neurosci. 17:2003;1403-1410.
33. Levey A.I., et al. Localization of muscarinic m3 receptor protein and M3 receptor binding in rat brain. Neuroscience. 63:1994;207-221.
34. Caulfield M.P. Muscarinic receptors - characterization, coupling and function. Pharmacol. Ther. 58:1993;319-379.
35. Eglen R.M., et al. Muscarinic receptor subtypes and smooth muscle function. Pharmacol. Rev. 48:1996;531-565.
36. Schwartz M.W., et al. Central nervous system control of food intake. Nature. 404:2000;661-671.
37. Bayer L., et al. Rat diencephalic neurons producing melanin-concentrating hormone are influenced by ascending cholinergic projections. Neuroscience. 91:1999;1087-1101.
38. 3-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:2002;R1443-R1449.
39. 4 in carbamylcholine-induced gallbladder contractility. J. Pharmacol. Exp. Ther. 301:2002;643-650.
40. 3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci. 22:2002;10627-10632.
41. 5 receptor: a silent or emerging subtype? Br. J. Pharmacol. 130:2000;13-21.
42. Forster G.L., et al. M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J. Neurosci. 22:(RC190):2002;1-6.
43. 5 muscarinic acetylcholine receptor attenuates morphine reinforcement and withdrawal but not morphine analgesia. Proc. Natl. Acad. Sci. U. S. A. 99:2002;11452-11457.
44. Faraci F.M., Sigmund C.D. Vascular biology in genetically altered mice: smaller vessels, bigger insight. Circ. Res. 85:1999;1214-1225.
45. Phillips J.K., et al. Variation in mRNA expression of alpha-adrenergic, neurokinin and muscarinic receptors amongst four arteries of the rat. J. Auton. Nerv. Syst. 62:1997;85-93.
46. Elhusseiny A., et al. Functional acetylcholine muscarinic receptor subtypes in human brain microcirculation: identification and cellular localization. J. Cereb. Blood Flow Metab. 19:1999;794-802.
47. Geaney D., et al. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet. 335:1990;1484-1487.
48. Tong X.K., Hamel E. Regional cholinergic denervation of cortical microvessels and nitric oxide synthase-containing neurons in Alzheimer's disease. Neuroscience. 92:1999;163-175.
49. Scremin O.U., Jenden D.J. Cholinergic control of cerebral blood flow in stroke, trauma and aging. Life Sci. 5:1996;2011-2018.
50. Kano M., et al. Parasympathetic denervation of rat pial vessels significantly increases infarction volume following middle cerebral artery occlusion. J. Cereb. Blood Flow Metab. 11:1991;628-637.
51. Vilaro M.T., et al. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci. Lett. 114:1990;154-159.
52. Weiner D.M., et al. Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. Proc. Natl. Acad. Sci. U. S. A. 87:1990;7050-7054.
53. Raiteri M., et al. Heterogeneity of presynaptic muscarinic receptors regulating neurotransmitter release in the rat brain. J. Pharmacol. Exp. Ther. 228:1984;209-214.
54. 5 muscarinic receptor knock-out mice. J. Neurosci. 22:2002;6347-6352.
55. Wise R.A. Neurobiology of addiction. Curr. Opin. Neurobiol. 6:1996;243-251.
56. Koob G.F., et al. Neuroscience of addiction. Neuron. 21:1998;467-476.
57. Oakman S.A., et al. Distribution of pontomesencephalic cholinergic neurons projecting to substantia nigra differs significantly from those projecting to ventral tegmental area. J. Neurosci. 15:1995;5859-5869.
58. Gerlai R. Gene-targeting studies of mammalian behavior: is it the mutation or the background genotype? Trends Neurosci. 19:1996;177-181.
59. Duttaroy A., et al. Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol. Pharmacol. 62:2002;1084-1093.
60. 4 receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J. Pharmacol. Exp. Ther. 292:2000;877-885.
61. Zhang W., et al. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci. 22:2002;1709-1717.
62. 2 muscarinic acetylcholine receptor knockout mice. J. Pharmacol. Exp. Ther. 303:2002;99-103.
63. Bernardini N., et al. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of nociception. J. Neurosci. 22:(RC229):2002;1-5.
64. 4-receptor-deficient mice. Br. J. Pharmacol. 138:2003;469-480.
65. Matsui M., et al. Increased relaxant action of forskolin and isoproterenol against muscarinic agonist-induced contractions in smooth muscle from M2 receptor knockout mice. J. Pharmacol. Exp. Ther. 305:2003;106-113.
66. 2-muscarinic receptors in control of the kinetics of acetylcholine release. J. Neurophysiol. 89:2003;1954-1967.
67. 4-receptor-deficient mice. Naunyn Schmiedebergs Arch. Pharmacol. 365:2002;112-122.